Table 2.

Effects of different pharmacological treatments, in the absence or presence of kaempferol (3 × 10⁻⁶ M), on the EC₅₀ and E_max values of concentration–relaxation curves of bradykinin (10⁻¹¹ to 10⁻⁶ M) in porcine coronary arteries contracted by U46619 (3 × 10⁻⁸ M)

Treatment	EC50 (log M)		Emax (%)
	Vehicle (ethanol, 0.1%)	Kaempferol (3 × 10−6 M)	Vehicle (ethanol, 0.1%)	Kaempferol (3 × 10−6 M)
Control	−8.3 ± 0.2	−8.9 ± 0.1#	105 ± 3.0	106 ± 2.2
L-NAME (10−4 M)	−7.2 ± 0.2*	−7.6 ± 0.2	68 ± 9.0*	79 ± 3.1*
ODQ (10−5 M)	−7.3 ± 0.1*	−7.8 ± 0.4	73 ± 12*	81 ± 7.5*
TRAM-34 (10−6 M) + UCL 1684 (10−6 M)	−8.2 ± 0.1	−8.7 ± 0.1#	94 ± 4.0	107 ± 4.2
Iberiotoxin (3 × 10−7 M)	−8.1 ± 0.2	−8.3 ± 0.2	100 ± 1.3	100 ± 1.7

n = 6–8 in each group.

^*P < 0.05 versus control group

^#P < 0.05 versus respective group without kaempferol. Iberiotoxin, inhibitor of large-conductance calcium-activated potassium channels; L-NAME, inhibitor of NOS; ODQ, inhibitor of soluble GC; TRAM-34, inhibitor of intermediate-conductance calcium-activated potassium channels; UCL 1684, inhibitor of small-conductance calcium-activated potassium channels.